Within the past few years, studies on microRNA (miRNA) and cancer have burst onto the scene. Profiling of the miRNome (global miRNA expression levels) has become prevalent, and abundant miRNome data are currently available for various cancers. The pattern of miRNA expression can be correlated with cancer type, stage, and other clinical variables, so miRNA profiling can be used as a tool for cancer diagnosis and prognosis. miRNA expression analyses also suggest oncogenic (or tumor-suppressive) roles of miRNAs. miRNAs play roles in almost all aspects of cancer biology, such as proliferation, apoptosis, invasion/metastasis, and angiogenesis. Given that many miRNAs are deregulated in cancers but have not yet been further studied, it is expected that more miRNAs will emerge as players in the etiology and progression of cancer. Here we also discuss miRNAs as a tool for cancer therapy.
INTRODUCTION
MicroRNAs (miRNAs) are small noncoding regulatory RNAs ranging in size from 17 to 25 nucleotides (see miRBase, http://microrna. sanger.ac.uk/). The definition of miRNAs is based on their generation by the action of Dicer, an RNase that processes hairpin-structured precursors (known as pre-miRNA) into mature miRNAs (5) . miRNAs posttranscriptionally repress gene expression by recognizing complementary target sites in the 3 untranslated region (UTR) of target messenger RNAs (mRNAs).
Eight years after the first miRNA was reported by Ambros's and Ruvkun's groups (3, 4) in 1993, the miRNA era began in earnest when three groups identified tens of small RNAs from Caenorhabditis elegans, Drosophila, and human (6) (7) (8) . During the past seven years, the number of miRNAs identified, as well as the number of publications describing them, has expanded enormously.
Genes, Sequences, and Genomic Organization
Currently, more than 5000 miRNAs from over 50 organisms are registered in the miRBase database (8a). Five hundred thirty-three human miRNAs are now known, but this number may increase, as bioinformatics studies predict that up to 1000 miRNAs exist (9, 10) . miRNAs are named as miR-plus numbers (e.g., miR-125), although there are a few exceptions. miRNAs of similar sequence are usually distinguished by an additional letter following the miRNA number (e.g., miR-125b). A miRNA of identical mature sequence may appear at several genomic loci with different precursor sequences. In such a case, the different miRNA genes would be distinguished by the addition of another number at the end of the sequence (e.g., miR-125b-1).
In humans, approximately one-third of miRNAs are organized into clusters. A given cluster is likely to be a single transcriptional unit, suggesting a coordinated regulation of miRNAs in the cluster. In silico analysis has revealed that more than half of the clusters contain two or more miRNAs of similar sequence (11) . However, it is very rare for miRNAs of an identical mature sequence to be duplicated in a cluster. This genomic organization confers simultaneous expression of similar miRNAs, possibly leading to combinatorial diversity and synergy in the biological effects. However, all the miRNAs from a single transcriptional cluster are not expressed at equal levels, suggesting that miRNAs are also regulated posttranscriptionally. Also, a significant portion of miRNAs are located in the intronic region of protein-coding or -noncoding transcription units (12) , whereas a minor subset of miRNAs are mapped to repetitive sequences such as long interspersed nuclear elements (13) .
Expression
Many miRNAs exhibit characteristic expression patterns. Some miRNAs are differentially expressed in developmental stages, for instance the two founding members lin-4 and let-7 in C. elegans. For this reason, they were once known as small temporal RNAs because they are expressed in specific temporal phases of development and regulate developmental timing. Many miRNAs are expressed in a tissue-specific manner. In the few cases where a forward genetic approach in worms or flies led to identification of a miRNA, the function of the miRNA was inferred from the phenotype of the mutant. In mammalian cells, however, a miRNA expression profile is usually the first clue to its possible role. Analogous to mRNA expression, miRNA expression is determined by intrinsic cellular factors as well as diverse environmental variables.
Expression of a miRNA can be measured by molecular biology techniques, such as Northern blot, RNase protection assay, and primer extension assay. The small size of miRNAs initially hampered polymerase chain reaction (PCR)-based methods. However, since the development of adaptor-mediated quantitative real-time PCR (qRT-PCR; reviewed in Reference 14) , PCR-based techniques have become very popular due to their high sensitivity. Microarray techniques (reviewed in Reference 15) are widely used to comprehensively assay the entire miRNome (the global miRNA expression profile) in tissues or in cell lines ( Table 1) . In addition to microarray and qRT-PCR, both in situ hybridization (16) and serial analysis of gene expression (SAGE) adapted for small RNAs (17) have been used to obtain miRNomes. Interest in the SAGE approach was stimulated by recent innovations in ultrahighthroughput sequencing that provide a powerful tool for various genomics studies. Overall, these technical improvements are expected to greatly widen the repertoire of miRNAs in a variety of biological systems. 
Biogenesis
Biogenesis of a miRNA begins with the synthesis of a long transcript known as a primiRNA (Figure 1) . In general, pri-miRNAs are transcribed by RNA polymerase II and retain mRNA features such as 5 cap structure and 3 poly(A) tail (18, 19) . However, other pathways generate in a minor set of miRNAs, especially from genomic repeats. For example, RNA polymerase III is responsible for transcription of miRNAs in Alu repeats (20) .
In the nucleus, pri-miRNA is processed to pre-miRNA by RNase III enzyme Drosha and its interacting partner DGCR8 (DiGeorge syndrome critical region gene 8) (21) (22) (23) . DGCR8 recognizes the stem and the flanking singlestranded RNA (ssRNA) and serves as a ruler for Drosha to cut the stem approximately 11 nucleotides away from the stem-ssRNA junction to release the hairpin-shaped pre-miRNA (24) . A subset of miRNAs known as miRtrons bypass the Drosha requirement by taking an alternative pathway, where pre-miRNAs are derived as a byproduct of a splicing event (25) (26) (27) . The pre-miRNA is exported by exportin-5 to the cytoplasm (28, 29) and is subsequently converted to mature duplex miRNA by another RNase III enzyme, Dicer (30) . The two strands of the duplex are separated by a RNA helicase (31) during the specific assembly of a ribonucleoprotein complex containing miRNA (miRNP). As with the strand selection of a siRNA (32, 33) , the strand whose 5 end forms the more unstable duplex with its partner seems to preferentially survive as the miRNA in the miRNP (24, 32, 33) . However, the detailed molecular events that take place during the miRNP assembly and strand selection are not yet clear.
Mechanisms of Action
miRNAs posttranscriptionally suppress the target mRNA expression, mostly through interaction with the 3 UTR (Figure 1) . However, the exact mechanism for miRNAs on their targets (reviewed in Reference 34) is still controversial. In contrast to the perfect sequence complementarity between siRNA and mRNA, there are mismatches and bulges in most miRNA target sites. Comparison between siRNA and miRNA in earlier papers suggested that siRNA destabilizes mRNA, whereas miRNA inhibits mRNA translation without affecting the mRNA level. Therefore, the degree of complementarity between short RNA and the target was thought to be a major determinant distinguishing the two mechanisms.
Although the translational repression mechanism still holds true for many miRNAs, it has also been demonstrated (35) (36) (37) (38) ) that a miRNA can decrease the level of a target mRNA despite imperfect sequence complementarity between the miRNA and the target. mRNA degradation by a miRNA, which is distinguished from siRNA-mediated mRNA cleavage, can be explained by mRNA-processing bodies (P-bodies), which are sites for RNA decay (39, 40) . Plausibly, miRNAs inhibit translation of target mRNAs, which are then sequestered to P-bodies and become subject to degradation. This model fits well for both mechanisms, although miRNAs have also been proposed to lead to the degradation of the target mRNAs without sequestration to P-bodies (41, 42) . In some cases where mRNA translation is inhibited by a miRNA but where mRNA levels remain similar, sequestration to P-bodies might be inefficient. Nonetheless, it is possible that different mechanisms apply to individual miRNA-mRNA interactions.
Target Prediction and Identification
Prediction of miRNA targets (reviewed in Reference 46) is important, given that miRNAs exert their function by regulating target mRNAs. The specificity of miRNA-mRNA interaction is mainly conferred by the first eight nucleotides of a miRNA (known as a seed sequence) (43) . The likelihood that a predicted target is a bona fide target is influenced not only by seed pairing but also by other factors such as the number of target sites, the context of surrounding sequence in mRNA (44) , and the occlusion of target sites by RNA-binding proteins (45) . Currently, several computational algorithms (reviewed in Reference 46) can predict the target mRNA(s), but they are far from perfect. The gold standard is experimental demonstration that (a) a luciferase reporter fused to the 3 UTR of the predicted target is repressed by overexpression of the miRNA and (b) this repression is abrogated by point mutation in the target sequence(s) in the 3 UTR. Many targets are predicted by in silico analyses, but not all of them are confirmed as real targets in this biological assay.
The in silico predictions have been complemented by experimental screenings for targets of miRNAs. Because miRNAs destabilize HMGA2: highmobility group AT-hook 2 mRNAs, miRNA depletion by a knockdown of miRNA-processing machinery is expected to result in upregulation of target mRNA, which can be assayed by microarray analysis. This approach identified HMGA2 (highmobility group AT-hook 2) as a target of let-7 (38) . Microarrays can also identify mRNAs that are decreased upon transfection of a miRNA, and screening these mRNAs for computationally predicted sites targeted by the miRNA yields some bona fide targets (37) . A proteomics approach to identify proteins decreased by miRNAs led to the identification of tropomyosin 1 as a miR-21 target (47). Another screen employed a library of miRNA-expressing vectors and a sensor plasmid containing green fluorescent protein fused with the 3 UTR of the gene of interest. p27(Kip1) was found to be targeted by miR-221 and -222 by this approach (48) . Another approach is to isolate the miRNA-target mRNA complex by immunoprecipitation of a component of RNA-induced silencing complex (RISC) followed by microarray hybridization of the precipitated mRNAs (49) .
Although a growing number of miRNAtarget pairs are being identified (Table 2), the fraction of validated pairs is still small, given that 30% of mRNAs have been predicted to be miRNA targets (50, 51) . New target identification will be facilitated by the accumulation of validated miRNA-target pairs, which can be utilized to develop a better prediction algorithm. In addition, experimental tools for high-throughput target screening need to be improved.
Biological Roles
miRNAs play important roles in cell fate determination, proliferation, and cell death. In addition to these vital processes, miRNAs are implicated in diverse cellular activities, such as immune response (reviewed in References 52 and 53), insulin secretion (54), neurotransmitter synthesis (55), circadian rhythm (56), and viral replication (57). This list will undoubtedly expand as experimental data accumulate. Listed for each miRNA is its target gene(s). A directly regulatory connection was demonstrated between each miRNA and target a by a luciferase assay using the 3 untranslated region (UTR) of the mRNA. Abbreviations: AIB1, amplified in breast cancer 1; BART, BamH1 A rightward transcript; Ccnd2, cyclin D2; Ccne2, cyclin E2; CTGF, connective tissue growth factor; DNMT, DNA methyltransferase; EBV, Epstein-Barr virus; ERBB, v-erb-b2 erythroblastic leukemia viral oncogene homolog; E2F, E2F transcription factor; HCC, hepatocellular cancer; Hipk3, homeodomain-interacting protein kinase 3; HMGA, high-mobility group AT-hook 2; KSHV, Kaposi sarcoma-associated herpesvirus; LATS2, large tumor suppressor, homolog 2; MET, hepatocyte growth factor receptor; Mylip, myosin regulatory light chain-interacting protein; PTEN, phosphatase and tensin homolog; Rbp1-like, retinoblastoma-binding protein 1-like; THBS1, thrombospondin 1; TPM1, tropomyosin 1; trkC, tropomyosin-related kinase C; TβRII, transforming growth factor beta-receptor type II.
miRNA transfection results in up-and downregulation of a number of mRNAs. In several cases, a set of genes belonging to a particular cellular pathway are enriched in the genes whose expression was altered (35, (58) (59) (60) (61) (62) . The length of the miRNA seed sequence is comparable to that of the consensus sequence of transcription factor-binding elements. Thus, although miRNAs are expected to directly regulate a large set of genes simultaneously, random chance is unlikely to explain the enrichment of genes in a particular pathway in the list of putative targets.
MicroRNA AND CANCER

Profiling of MicroRNA Expression in Cancers
miRNAs are aberrantly expressed in a variety of cancers. This was first observed in miR-15a and -16-1, which are clustered at chromosome 13q14, a frequently deleted region in B cell chronic lymphocytic leukemia (CLL) and other cancers (63). Concomitantly, reduction of these two miRNAs was observed in the cancer samples relative to the normal tissues.
miRNome analyses have become easier with the introduction of microarray techniques ( Table 1) . Many miRNAs are found to be up-or downregulated in the cancer samples relative to the normal tissue counterparts (Supplemental Table 1 ; follow the Supplemental Material link from the Annual Reviews home page at http://www. annualreviews.org). It is beyond the capacity of this review to describe all the miRNAs that are changed in cancers from profiling data. Instead, in Table 1 we summarize the literature reporting miRNomes in tumors. If a change in miRNA expression has been corroborated by a conventional method (e.g., Northern blot, RNase protection assay, or qRT-PCR), it is indicated in Supplemental Table 1 .
In addition to the distinction of tumors from normal tissue, miRNA expression is characteristic for a cancer type, stage, and other clinical variables. The first systematic analyses of hundreds of cancer samples and normal tissues (64) successfully classified various cancers based on the miRNome. Surprisingly, the miRNome was better at predicting cancer type and stage than the mRNA expression profile; therefore, the miRNome has been proposed as a useful tool for cancer diagnosis and prognosis. For example, clustering of CLL samples according to the miRNome revealed miRNA signatures that correlate with overexpression of ZAP-70, a predictor of early disease progression (65). The utility of miRNA in diagnosis is discussed further below.
Although some miRNAs are increased, most are repressed in cancers relative to normal tissue counterparts (64, 66-69). In agreement with these observations, global depletion of miRNAs by knockdown of the miRNA-processing machinery stimulates cell transformation and tumorigenesis in vivo (70). This implies that the miRNA alteration is not simply an end result of tumorigenesis but that it actively contributes to cancer development. Despite the general reduction of miRNAs in cancers, several miRNAs are upregulated, some of which undoubtedly play oncogenic roles.
Mechanism for MicroRNA Deregulation in Cancers
As described in the previous section, many miRNAs are deregulated in cancers. Aberrant expression of miRNAs can arise through a number of different mechanisms (Figure 2) . Genomic abnormalities. As exemplified by miR-15a and -16-1, chromosomal abnormality is one reason for miRNA deregulation in cancers. Tumorigenesis is often accompanied by chromosomal aberrations such as deletion, miRNA gene
Epigenetic regulation • CpG methylation • Histone modification
Transcription factor
Myc, E2Fs, p53, BCR-ABL,Twist, NF-κB, ER-α, AR, STAT3, ... amplification, and translocation. In silico analysis has revealed that a significant fraction of miRNAs are mapped to these cancer-associated genomic regions or fragile sites in human (71) and in mouse (72). In many cases, miRNA levels are correlated with changes in copy number of the genomic loci, as demonstrated by comparison between array comparative genomic hybridization data and miRNA expression data (66, 73-78).
Genomic abnomalities
Epigenetic factors. Epigenetic factors can also affect miRNA expression. In many cancers, hypermethylation of CpG islands in promoter regions results in heritable transcriptional silencing of tumor-suppressor genes. Gene silencing by DNA methylation is closely related to histone modification. In silico analyses have indicated CpG islands near dozens of miRNAs (79) . In addition, some miRNAs are upregulated (a) upon the exposure of cells to the demethylating agent 5-aza-2 -deoxycytidine (79), (b) upon mutation of DNA methyltransferases (DNMTs) (80) , and (c) upon histone deacetylase inhibitor treatment (81) . These studies have identified some miRNAs that are repressed by CpG hypermethylation in cancers relative to normal tissue. Representative examples include miR-9-1 in breast cancer (79) and miR-124a in colorectal tumors (80) . In the case of miR-124a, hypermethylation is tumor type specific, as no methylation is seen in neuroblastoma. Also, epigenetic silencing of a miRNA may be a reflection of tissue specificity. For example, miR-124a is normally highly expressed in neuronal tissues, so its epigenetic repression in colorectal tumors is not surprising. miRNAs may counteract CpG methylation. For example, miR-29 directly targets DNMT-3A and -3B. In agreement with this observation, ectopic expression of miR-29 results in a global reduction of DNA methylation, subsequently leading to a depression of tumorsuppressor genes that had been silenced by promoter methylation in cancer cells (82) .
Transcriptional regulation. Transcription factors may induce miRNAs by activating the transcription of pri-miRNAs. This mechanism has been well documented in several cases where tissue-specific miRNAs are turned on by transcription factors during differentiation. Given the wide impact of transcription factors on fundamental cellular processes, it is not surprising that many oncogenes or tumor suppressors are transcription factors. Many miRNA-transcription factor relationships have been discovered in cancers (listed in Table 3 ). We discuss three of these-p53, c-Myc, and E2F-in detail below.
Regulation at microRNA processing steps.
The steady-state level of a mature miRNA is determined not only by the transcription rate of pri-miRNA but also by the processing efficiency of its precursors and by its stability. miRNAs often exhibit a discrepancy in expression of the mature form relative to that of the precursor (83) (84) (85) (86) (87) (88) . Although miRNAs in a genomic cluster are usually expressed from a common pri-miRNA, the levels of individual miRNAs in the cluster are not necessarily coordinated (89, 90) . A time-course experiment after induction of pri-miR-21 revealed delayed kinetics in accumulation of mature miR-21 (91) . Collectively, these observations indicate that miRNA processing and stability are important factors that determine miRNA expression level. This mechanism has been confirmed in cancers by a comprehensive analysis of expression data (92). As stated above, miRNAs are generally reduced in cancers relative to the normal tissues. When a miRNA resides within a gene, the host gene can be regarded as the primiRNA. Comparison of microarray data between mRNA and miRNA revealed that the miRNA reduction in cancers is poorly correlated with a reduction of the host gene expression. Aberrant expression of miRNAs during tumorigenesis is presumably often due to alterations at posttranscriptional steps.
The expression levels of Dicer or Drosha are altered in a number of cancers (70, [93] [94] [95] [96] . Drosha upregulation is seen in more than half of cervical squamous cell carcinoma (SCC) specimens and is likely due to the copy number gain at chromosome 5p, where the Drosha gene is located (95) . Hierarchical clustering of miRNA expression data successfully classified cervical SCC samples into two groups according to Drosha overexpression. Notably, some miRNAs were reduced upon Drosha overexpression, indicating that individual miRNAs respond differentially to an elevation of the miRNA processing machinery. Interestingly, Drosha was reported to interact with an oncogenic fusion protein derived from a chromosomal translocation in some leukemias (97) . This interaction affects pri-miRNA selection of Drosha and, as a result, influences miRNA expression patterns.
Consequence of Aberrant
Since the publication of a study showing that let-7 miRNA directly regulates RAS oncogene (98), a number of other miRNA-target pairs have been studied. However, the number of experimentally validated pairs is still small relative to (a) the number of miRNAs shown to be aberrantly expressed in tumors and (b) the number of in silico predicted pairs, mostly because current target prediction algorithms are not very accurate. A current list of miRNA-target pairs implicated in various cancers is given in Table 2 , and important examples are discussed below.
If we compare global gene expression profiles in cancers and normal tissues, we find that many miRNAs and mRNAs are deregulated. Therefore, it is plausible that tumorigenesis (or at least the progression of a cancer) results from changes in the entire miRNome, rather than from the change of a single miRNA that regulates an oncogenic (or tumor-suppressive) target gene.
Some miRNAs appear to be deregulated in cancers much more frequently than others (Supplemental Table 1 ). These miRNAs may play key roles during tumorigenesis. For example, the miR-17-92 cluster and miR-155 have been shown experimentally to be bona fide oncogenes, as their ectopic expression accelerates tumor development. These two miRNAs are discussed in detail in separate sections.
Aberrant Action of MicroRNAs Without Alteration of MicroRNA Expression Level
The function of protein-coding genes is rendered abnormal by point mutations, which either transform proto-oncogenes to oncogenes or abrogate functions of tumorsuppressor genes. In theory, the same mechanism of activation/inactivation may apply to miRNAs. However, mutation in mature miRNA sequence seems to be a rare event (72, 99-101), presumably due to the small size of the mature miRNA. In addition, miRNAs are thought to be more tolerant of point mutations or of single nucleotide insertion/deletion mutations than of protein-coding genes.
In contrast, sequence variation in miRNA target sites may occur and may play a role in cancer. In silico analyses of expressed sequence tag and single nucleotide polymorphism (SNP) databases indicate different allele frequencies of miRNA-binding sites in cancers versus normal tissues (102) . Several experiments have shown that sequence polymorphisms in miRNA target sites affect miRNA-mRNA interaction and are implicated in disease phenotypes (100, 103-105) (Figure 2 ).
An interesting illustration of this mechanism can be found in let-7 and its direct target oncogene, HMGA2 (38, 106) . Chromosomal rearrangements at the HMGA2 locus in several tumors separate the open reading frame (ORF) from the 3 UTR that contains let-7 target sites. As a result, HMGA2 escapes from suppression by let-7, is overexpressed, and promotes tumorigenesis (Figure 2 ).
An alternative splicing event may result in a different 3 UTR that displays different miRNA target sites, as exemplified in the targeting of tropomyosin-related kinase C by miR-9, -125a, and -125b. One mRNA isoform encodes a truncated ORF that is functionally dominant negative to the intact protein. In this isoform, the 3 UTR contains the target sites of these miRNAs. In contrast, the target sites are absent in another isoform encoding the intact ORF; only the former isoform was repressed by the KSHV: Kaposi sarcoma-associated herpesvirus miRNAs (107) . Although the stop codon is usually located in the last exon, generation of different 3 UTRs by multiple polyadenylation sites or alternative splicing has been known to occur in a small but significant fraction of genes (108) . Thus, variation of 3 UTR and of attendant miRNA target sites is expected to be a mechanism for oncogene activation or tumorsuppressor inactivation (Figure 2) .
Recently, Steitz and colleagues (109) reported that miRNAs activate the translation of the target mRNA in cells arrested at the G 0 /G 1 stage. In addition to aberrant miRNA expression, the switch from repression to activation should be considered in studying the role of miRNAs in differentiation or tumorigenesis, as the same miRNA may exert opposite effects in resting cells and proliferating cancer cells in a given tissue.
Viruses and MicroRNAs in Tumorigenesis
Several viruses regulate tumorigenesis by expressing viral oncogenes or by activating cellular oncogenes through integration of viral DNA into genomic loci. Both mechanisms are applicable to oncogenic miRNAs. For example, Epstein-Barr virus (EBV)-encoded miRNAs (110) directly target a viral oncogene, LMP1, whose overexpression is deleterious to host cells. EBV-encoded miRNAs are thought to enhance EBV-mediated cellular transformation by adjusting LMP1 level to a sublethal dose (111) . Another study showed that a viral miRNA repressed a host tumor-suppressor gene. In this study, miRNAs from Kaposi sarcoma-associated herpesvirus (KSHV) directly targeted an antiangiogenic factor, thrombospondin-1 (Tsp-1) (112). Thus viral miRNAs act as viral oncogenes.
Viral integration near miRNA loci may lead to aberrant expression of miRNAs. Indeed, the BIC locus harboring miR-155 was originally described as a frequent integration site in virally induced lymphomas (113) . Viral integration sites are often mapped to miRNA loci (114) such as the miR-17-92 cluster (115), the www.annualreviews.org • MicroRNAs in CancermiR-106a-363 cluster (116) , the miR-29a-29b-1 cluster (117) , and the miR-106a cluster (118) .
Various Cancer Types
Comprehensive miRNA profiles have been reported in clinical specimens from various cancers ( Table 1) . Consistent with the notion that miRNAs are expressed in a tissue-specific manner, miRNAs differ among cancers from various tissue origins. Also, a few miRNAs appear to be frequently deregulated in many cancers (Supplemental Table 1 ), suggesting that these miRNAs regulate fundamental processes such as cell proliferation and apoptosis.
Oncogenic or Tumor-Suppressive MicroRNAs miR-17-92 cluster.
The miR-17-92 cluster, located at chromosome 13q31.3 in humans, is composed of six miRNAs (mir-17, -18a, -19a, -20a, -19b-1, and -92a-1). There exists a similar cluster at chromosome 10 known as miR106a-363, which also contains six miRNAs (mir-106a, -18b, -20b, -19b-2, -92a-2, and -363). The miR-17-92 cluster contains the first miRNAs demonstrated to be oncogenic. The development of B cell lymphoma is significantly accelerated by the forced expression of the miR-17-92 cluster in transgenic mice overexpressing the c-myc oncogene (119).
Consistent with its oncogenic role, the miR-17-92 cluster is upregulated in a variety of cancers including lymphomas (74, 75, 119, 120), lung cancers (77, 121), and others (122). There appear to be two mechanisms for upregulation of this cluster in cancers (Figure 3) . One is the amplification of the chromosome 13q31 locus in several lymphomas and other cancers (74, 77, 78, 120). The other is transcriptional activation of the pri-miRNA, wherein an oncogenic transcription factor c-Myc binds the genomic locus upstream of the miR-17-92 cluster and activates its expression (123). In neuroblastoma cells, MYCN, a protein highly homologous to c-Myc, appears to activate this cluster instead of c-Myc (124). E2Fs also activate this cluster (125, 126) ( Table 3 ).
Given that the E2Fs are direct targets of miR-17 and -20a, the miR-17-92 cluster constitutes a complex regulatory network with c-Myc and E2Fs. E2F1 and c-Myc are known to activate each other to form a positive feedback loop 
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The miR-17-92 pathway. ( Figure 3) . All of the E2Fs (E2F1, -2, and -3) are capable of activating the miR-17-92 cluster and are subject to repression by miR-17 and -20a from this cluster ( Table 2) . However, degrees of activation and repression vary between individual pairs of miRNA and E2F family members. In general, E2Fs are thought to be proproliferative, but E2F1 is also proapoptotic. Although this network is too complicated to describe in a straightforward manner, the miR-17-92 cluster is clearly responsible for fine-tuning the regulatory network. Upon a proliferative cue, c-Myc and E2Fs turn on the miR-17-92 cluster. This cluster represses E2Fs, thereby preventing the uncontrolled amplification of the positive feedback loop between E2Fs and c-Myc. In addition, repression of E2F1 by the miRNAs may help minimize the proapoptotic potential of E2F1. This network is depicted in Figure 3 . Table 1 ). miR-21 is transcriptionally activated by signal transducer and activator of transcription 3 (Stat3) in the interleukin-6 signaling pathway (91) ( Table 3) . miR-21's role in invasion and metastasis is well characterized and is discussed further below.
miR-21. miR-21 is upregulated in almost all kinds of cancers (Supplemental
miR-155.
As with the miR-17-92 cluster, the oncogenic potential of miR-155 has been demonstrated by transgenic mice expressing miR-155 in B cells (127) . The primary transcript for miR-155 is the BIC gene, which was originally known as a common viral integration site in lymphomas in chicken. High expression of miR-155 (BIC) is reported in various B cell malignancies (128-130) (Supplemental Table 1 ). miR-155 seems to be regulated at multiple levels. miR-155 (BIC) appears to be regulated by nuclear factor-kappa B (NF-κB) through the B cell receptor-mediated signaling pathway (85) or through the Toll-like receptor-activated signaling pathway (131) . However, a discrepancy between the levels of miR-155 and BIC suggests that miR-155 may also be regulated during processing steps (129) . For example, the induction of BIC does not lead to upregulation of miR-155 in several Burkitt lymphoma cell lines. In contrast, miR-155 is concordantly increased upon the induction of BIC in Raji, an EBV-latency type III-positive Burkitt lymphoma cell line (85) .
let-7. let-7 is one of the earliest-discovered miRNAs. In human, there are 12 paralogous let-7s. let-7 is almost absent during embryonic stages or tissues, whereas high expression of let-7 is seen in most differentiated tissues. The reduction of let-7 in cancers is reminiscent of let-7 expression during development in that it is most decreased in less-differentiated, advanced stages of cancer cells with mesenchymal characters (132) . let-7 is probably more abundant than any other miRNA, so reduction of let-7 may have a prominent effect on cell physiology compared to other miRNAs. To support this hypothesis, enhanced cellular transformation by global miRNA depletion was largely recapitulated by inhibition of let-7 alone (70). Wellknown oncogenes such as RAS, c-Myc, and HMGA2 are validated as direct targets of let-7 ( Table 2) . Hence, let-7 is an important tumor suppressor.
miR-34s (miR-34a and miR-34b/-34c clusters).
The miR-34s recently acquired notoriety because they are induced by p53 (Figure 4) . Consistent with p53's role as a tumor suppressor, miR-34s are downregulated in several tumors such as non-small cell lung cancers (60) and pancreatic cancers (61) (Supplemental Table 1 ). However, reduction of the miR-34s is not always correlated with p53 loss, suggesting a p53-independent mechanism of miR-34 reduction in some cancers. In fact, miR-34a is located in 1p36, a locus that is frequently deleted in a number of cancers (76). We return to our discussion of p53 regulation and miR-34s' roles below.
Although the miR-34s are thought to be tumor suppressors, they have been found to be upregulated in several cancers including renal cell carcinoma (133) 
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The p53 and miR-34 pathway. Abbreviation: MET, hepatocyte growth factor receptor. hepatocellular carcinoma (134) (Supplemental Table 1 ). The role of high miR-34 and p53 status in these tumors awaits investigation.
Aspects of Cancer Biology Regulated by MicroRNAs
Cell cycle. Cell-cycle regulators often act as oncogenes or as tumor suppressors. The bestcharacterized example is the cell-cycle inhibitor p27(Kip1). p27(Kip1) is a tumor suppressor, as indicated by its low levels in some cancers. In addition, p27(Kip1) mutation predisposes cells to tumorigenesis upon exposure to carcinogens. p27(Kip1) binds to Cdk2-cyclin E and prevents G 1 -to-S transition. p27(Kip1) is a direct target of miR-221 and -222 in glioblastomas (48, 135) and in prostate cancer cells (136) . In these cancer cells, p27(Kip1) is anticorrelated with miR-221 and -222. Targeting p27(Kip1) is responsible for the proproliferative role of these miRNAs, as artificial knockdown of p27(Kip1) mirrors the phenotype of these miRNAs. miR-221 and -222 are overexpressed in other cancers (see Supplemental Table 1 ), suggesting that they play a role in a wide range of cancers.
In addition to regulating p27(Kip1), miRNAs regulate other cell-cycle proteins including Cdk6; Cdc25A; Ccnd2 (cyclin D2) (59); Cdk4 (62), a Rb-family protein (89) ; and p180 of DNA polymerase α (37). A number of miRNAs have been shown to perturb normal cell cycle when overexpressed or inhibited (37, 48, 62 , 70, 137-139) (Supplemental Table 2 ). However, oscillation of a miRNA during the normal cell cycle has not yet been reported.
Programmed cell death.
Apoptosis is an active process controlled by a gene expression program that varies depending on the biological context. Because a balance between proliferation and apoptosis is essential for tissue homeostasis and proper differentiation, aberrant apoptosis may give rise to tumors. miRNAs participate in tumorigenesis by directly targeting antiapoptotic genes. Representative examples include the repression of antiapoptotic genes Mcl-1 and Bcl-2 by miR-29b (84) and by miR-34s (60), -15a, and -16 (140), respectively ( Table 2 ). The loss of these miRNAs due to mutation of p53 or deletion of chromosome 13q14 leads to an increase in the antiapoptotic gene expression and persistence of tumor cells that would normally have been removed by apoptosis. It is very likely that miRNAs target other genes in the apoptotic pathway, as transfection or expression of a number of miRNAs is associated with apoptosis (69, 76, 121) (Supplemental Table 2 ).
p53. p53, a sequence-specific transcription factor, is known as the guardian of the genome owing to its critical role in regulation of the cell cycle and apoptosis in the face of genomic damage. Genotoxic stress and oncogene activation activate p53 to modulate the transcription of several target genes. p53 is the most extensively studied tumor suppressor and its importance is underscored by mutation of p53 in almost 50% of human cancers. miRNA profiling after p53 induction indicated miR-34a, -34b, and -34c (collectively, the miR-34s) as the most upregulated miRNAs (61, 62, 137, 141) (Figure 4) . These miRNAs are induced after genotoxic stress in a p53-dependent manner in vitro and in vivo (62, 141). miR34b and -34c are clustered at chromosome 11, whereas miR-34a is located in a separate genomic locus. Both pri-miRNAs are directly activated by p53. The miR-34s seem to be critical downstream effectors of p53, as ectopic expression of the miR-34s recapitulate the phenotype of p53 activation. The miR-34s promote cellcycle arrest, apoptosis, and senescence (58, 60-62, 137, 141) (Supplemental Table 2 ). These effects are explained by the repression of several direct targets of the miR-34s such as Bcl-2 (60), Cdk4, and hepatocyte growth factor receptor (62) ( Table 2) .
In addition to the miR-34s, other miRNAs may be important in the p53 pathway. miR30c, -103, -26a, -107, and -182 were induced clearly, albeit less robustly, upon DNA damage in a p53-dependent manner (61). miR-26a expression was also shown to be dependent on p53 (142) . In another approach, searching for p53-binding elements in DNA sequence near miRNAs identified miR-129 as a good candidate for regulation by p53 (143) .
Invasion and metastasis.
Features of malignant tumors, distinct from benign tumors, include invasion and metastasis. Malignant tumors are fatal, mostly due to their capacity to invade neighboring tissues and metastasize through the bloodstream to distant organs. An effect of miRNAs on invasion and migration has been reported (Supplemental Table 2 ). Ectopic expression of miR-125 impairs cell motility and invasion in a breast cancer cell line (144) , and reduction of global miRNA expression enhances migration of cells (70).
These sporadic in vitro observations were followed by more detailed studies on miR10b and miR-21. miR-21 is one of the most frequently upregulated miRNAs in cancers (Supplemental Table 1 ). It promotes cell motility and invasion by directly targeting PTEN (phosphatase and tensin homolog), a tumor suppressor known to inhibit cell invasion by blocking the expression of several matrix metalloproteases (134) . Another pathway was recently reported in colorectal cancers, where miR-21 promotes invasion, intravasation, and metastasis by downregulating Pdcd4 (145) . miR-10b is the other miRNA implicated in metastasis. In metastatic breast cancer cells, miR-10b is upregulated, presumably as a result of transcriptional activation by a transcription factor, Twist. Ectopic expression of miR-10b promotes invasion, intravasation, and metastasis in otherwise noninvasive or nonmetastatic breast cancer cell lines. miR-10b directly targets HOXD10, whose reduction induces the expression of a well-characterized prometastatic gene, RhoC (146). for promoting angiogenesis (147). A recent observation indicates that other miRNAs-miR-378 and -27a-may play a role in angiogenesis (139, 148) (Supplemental Table 2 ). Viral miRNAs may also play a role in angiogenesis, as Tsp-1 has been shown to be a direct target of KSHV miRNAs (112) .
Others. The microenvironment inside a solid tumor is usually hypoxic. Tumor cells under hypoxia tend to be resistant to therapies and to have a poor prognosis. Upregulation of certain miRNAs under hypoxia (149, 150) ( Table 3) suggests that these miRNAs may influence the phenotype of hypoxic tumor cells. Cancers are predisposed by other external factors, such as genotoxic stress, a folate-deficient diet, and exposure to arsenic. There are a few reports of miRNA profiles under these conditions (151, 152), but whether miRNA changes are responsible for the cancer predisposition remains to be investigated.
Clinical Applications
Diagnostic tools. miRNAs may be used as diagnostic or prognostic tools, as miRNA expression profiles reflect tumor origin, stage, and other pathological variables. miRNAs can function as accurate molecular markers because they are relatively stable and resistant to RNase degradation-probably because of their small size (35, 153, 154) . Researchers have shown that miRNAs can be isolated and quantitated from formalin-fixed paraffin-embedded (FFPE) specimens. qRT-PCR and microarray data were reliably and reproducibly obtained from FFPE samples that had been routinely processed and stored for 10 years. The data from FFPE samples are consistent with those from frozen samples (155, 156).
The development of qRT-PCR methods has improved the sensitivity of miRNA detection down to a few nanograms of total RNA (68, 157, 158). This amount can easily be obtained by fine-needle aspiration biopsies (FNABs); in fact, there has been a report of successful miRNA measurement by qRT-PCR on FNAB samples (159).
miRNA markers that could be used for cancer diagnosis are becoming available. For example, miR-196a is high in pancreatic ductal adenocarcinoma (PDAC) but low in normal tissues and chronic pancreatitis. miR-217 exhibits the opposite expression pattern (Supplemental Table 1 ). Thus, the ratio of miR-196a to miR-217, calculated by qRT-PCR measurement of the two miRNAs from a tiny amount of total RNA, indicates whether the sample contains PDAC (160). Once reliable indicator miRNAs are chosen, they will likely yield easy and accurate tools for cancer diagnosis.
Cancer therapeutic tool. A number of miRNAs affect the growth of cancer cells in vitro and in vivo when overexpressed or inhibited. Therefore, cancer cell growth can be controlled by manipulating miRNAs. Overexpression or inhibition of miRNAs can be achieved in several ways. Synthetic miRNA mimics include siRNA-like oligoribonucleotide duplex (161) and chemically modified oligoribonucleotide (162). Conversely, miRNAs can be inhibited by variously modified antisense oligonucleotides such as 2 -O-methyl antisense oligonucleotide, antagomirs, and so on (reviewed in Reference 163). As the first successful tool for knockdown of a miRNA in vivo, antagomirs are of special interest (164). Antagomirs appear to be delivered to all tissues (except brain) after tail-vein injections into mice. The therapeutic value of an antagomir would be greatly enhanced by technical improvements for selective tumor-specific or tissue-specific delivery.
Synthetic oligonucleotides are effective in vivo for at most a couple of weeks, as has been demonstrated by experiments involving cancer cells engrafted in mice (165) target sequence was shown to inhibit the miRNA function, presumably by titrating the miRNA away from endogenous targets (168, 169). Thus it should be possible to apply such competitive inhibitors for long-term sequestration of a miRNA. Nonspecific side effects are as important as effectiveness and duration of miRNA expression (or inhibition). Some investigators have argued that miRNA mimics or inhibitors are specific enough to distinguish between similar miRNAs (170, 171). However, cross-reactivity between miRNAs of similar sequence is likely to be unavoidable at high doses of antagonists or agonists. Another possible side effect is that high expression of miRNA mimics may interfere with endogenous miRNA action by saturating the cellular machinery for miRNA processing or action. This may result in a change in expression of other miRNAs, leading to a deleterious effect in the cells. Indeed, a fatal side effect as a result of saturation of miRNA pathway has been reported (172) . To minimize undesirable side effects, the expression or knockdown of a miRNA should be improved so that it is more accurate and controllable. An alternate approach to improving specificity is to target the pre-miRNAs with antisense or siRNA strategies (173, 174) .
Some chemical compounds alter expression of a group of miRNAs (81); therefore, it may be possible to screen for drugs that could shift the miRNome in a cancer cell toward that of the normal tissue. NCI-60 cancer cell lines may serve as a platform for this screening, as their miRNA expression profiles have been published (68, 175) . By modulating multiple miRNAs simultaneously, such a miRNomemodifying approach may be much more effective for therapy than strategies that aim to regulate a single miRNA.
miRNAs affect the drug sensitivity of a cell (165, 176) (Supplemental Table 2 ). Expression or inhibition of a miRNA can therefore be combined with treatment of a drug or other cytotoxic therapy. One example is miR-21 inhibition together with a secreted form of tumor necrosis factor-related apoptosis-inducing ligand, which results in a complete eradication of glioblastoma cells (177) .
Collectively, preliminary results suggest that miRNAs could be useful for cancer therapy. However, there is still a significant gap between basic research on miRNAs and clinical application. Extensive preclinical and translational research is necessary to increase the efficacy and decrease the side effects of miRNAs in vivo. In parallel, we need to expand our knowledge of the interactions between miRNAs and gene expression programs and how these interactions are altered in tumorigenesis.
CONCLUDING REMARKS
The discovery of miRNAs has added another dimension to the study of the regulation of gene expression. In addition to transcriptional regulation, posttranscriptional repression by miRNAs may act like rheostats for fine-tuning of gene expression. miRNAs at end stages of differentiation may contribute to keeping cells differentiated by suppressing a large number of genes simultaneously.
In recent years, there has been an explosion of publications on miRNAs. Many of these have emphasized the role of miRNAs in cancer biology. miRNAs play a role in almost all aspects of cancer biology, including proliferation, apoptosis, invasion/metastasis, and angiogenesis. New technical developments are enabling investigators to describe a variety of cancer miRNomes. Therefore, more miRNAs are expected to be identified as oncogenes or as tumor suppressors. Characterization of individual miRNA pathways will be greatly facilitated by an improvement of target prediction algorithms.
miRNA expression is associated with clinical variables of cancers, so miRNAs can be readily used as tools for cancer diagnosis and prognosis. For therapeutic benefit, the methods to manipulate miRNAs in vivo should become more robust. 3. miRNAs play roles in diverse aspects of cancer such as proliferation, apoptosis, invasion/metastasis, and angiogenesis.
4. Artificial expression/inhibition of a miRNA can be therapeutic.
APPENDIX Other Small RNAs?
In addition to siRNAs and miRNAs, other types of small RNA have been reported in yeast, Drosophila, C. elegans, and plants. These small RNAs include tiny noncoding RNAs, repeat associated small interfering RNAs, scan RNAs, and others (reviewed in Reference 178). These RNAs are thought to be related to miRNA and siRNA, but are distinct from them. Recently, Piwi-interacting RNA, another small RNA that is slightly larger than miRNA, was discovered from mammalian testes. Other classes of small RNA may exist but have yet to be discovered, given that a significant portion of transcripts are noncoding RNA. Whereas protein-coding genes comprise only 1-2% of the human genome, a significant fraction (∼15%) of the human genome is transcribed; these transcripts remain the "dark matter" of the genome (179, 180) . The discovery of noncoding RNAs is expected to be greatly accelerated by the widespread adaptation of high-throughput deep-sequencing techniques.
Other Diseases
miRNAs (or miRNA machinery) have been implicated in diseases other than cancer (182) , for example Tourette's syndrome, fragile X syndrome (181), DiGeorge syndrome (23), myotonic dystrophy, spinocerebellar ataxia type 3 (182) , and schizophrenia and schizoaffective disorder (183) . Of particular interest is myotonic dystrophy type 1, which is characterized by expansion of CTG repeat in the 3 UTR of the dmpk gene. Tandem CAG sequences are found in some miRNA seed sequences and thus are able to interact with the CTG repeats, raising the possibility that these miRNAs may be involved in DM1 pathogenesis (184) .
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